Stent grafts with bioactive coatings

• US 20050171594A1
• Filed: 11/03/2004
• Published: 08/04/2005
• Est. Priority Date: 12/31/1998
• Status: Abandoned Application

• Current Assignee: Angiotech Pharmaceuticals Incorporated, University of British Columbia
• Original Assignee: Angiotech Pharmaceuticals Incorporated, University of British Columbia
• Inventors: Hunter, William L., Machan, Lindsay S., Jackson, John K.
• Application Number:
  US10/981,391
• Publication Number:
  US 20050171594A1
• Time in Patent Office: Days
• US Class Current: 623/1.130
• CPC Class Codes: A61F 2/07 Stent-grafts
• CPC Class Codes: A61F 2/89 the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
• CPC Class Codes: A61F 2002/065 Y-shaped blood vessels
• CPC Class Codes: A61F 2002/075 the stent being loosely attached to the graft material, e.g. by stitching
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/00 Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
• CPC Class Codes: A61L 2300/412 Tissue-regenerating or healing or proliferative agents
• CPC Class Codes: A61L 2300/418 Agents promoting blood coagulation, blood-clotting agents, embolising agents
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

Stent grafts are provided comprising an endoluminal stent and a graft, wherein the stent graft releases an agent which induces the in vivo adhesion of the stent graft to vessel walls, or, otherwise induces or accelerates an in vivo fibrotic reaction causing said stent graft to adhere to vessel wall. Also provided are methods for making and using such stent grafts.

Claims

1-24. -24. (canceled)

25. A method for bypassing a diseased portion of a vessel, comprising delivering to a patient a stent graft to said diseased portion of the vessel such that vessel contents bypass said diseased portion of said vessel, wherein the stent graft comprises an endoluminal stent and a graft, wherein said graft is comprised of a material which is not released and which induces or accelerates an in vivo fibrotic reaction causing said stent graft to adhere to vessel walls.

37. The method of claim 25 wherein the graft material comprises a vessel wall irritant.

38. The method of claim 25 wherein the graft material comprises a component of extracellular matrix.

39. The method of claim 25 wherein the graft material comprises polylysine or ethylenevinylacetate.

40. The method of claim 25 wherein the stent graft is bifurcated.

41. The method of claim 25 wherein the stent graft is a tube graft.

42. The method of claim 25 wherein the stent graft is cylindrical.

43. The method of claim 25 wherein the stent graft is self-expandable.

44. The method of claim 25 wherein the stent graft is balloon-expandable.

45. The method of claim 25 wherein the graft material further comprises a textile.

46. The method of claim 25 wherein the stent graft further comprises a coating that delays the onset of fibrosis.

47. The method of claim 25 wherein the stent graft is activated from a previously inactive stent graft to a stent graft that induces or accelerates an in vivo fibrotic reaction.

48. The method-of claim 25 wherein the distal ends of said stent graft are adapted to release an agent that induces in vivo fibrosis.

49. The method of claim 48 wherein said agent comprises a vessel wall irritant.

50. The method of claim 49 wherein said vessel wall irritant is talcum powder.

51. The method of claim 49 wherein said vessel wall irritant is metallic beryllium.

52. The method of claim 49 wherein said vessel wall irritant is silica.

53. The method of claim 48 wherein said agent comprises a component of extracellular matrix.

54. The method of claim 48 wherein said agent is fibronectin.

55. The method of claim 48 wherein said agent is polylysine or ethyl enevinyl acetate.

56. The method of claim 48 wherein said agent is an inflammatory cytokine selected from the group consisting of TGFβ

, PDGF, VEGF, bFGF, TNFα

, NGF, GM-CSF, IGF-a, IL-1, IL-8, IL-6, and growth hormone.

57. The method of claim 48 wherein said agent is an inflammatory microcrystal.

58. The method of claim 48 wherein said agent is N-carboxybutyl chitosan.

59. The method of claim 48 further comprising a coating at the distal ends of said stent graft to delay the onset of adhesion or fibrosis.

60. The method of claim 48 wherein said agent is first activated from a previously inactive agent to an active agent.

61. The method of claim 25 wherein the distal ends of said stent graft are adapted to release an agent that induces in vivo adhesion.

62. The method of claim 61 wherein said agent is an adhesive.

63. The method of claim 62 wherein said adhesive is cyanoacrylate.

64. The method of claim 61 further comprising a coating at the distal ends of said stent graft to delay the onset of adhesion.

65. The method of claim 61 wherein said agent is first activated from a previously inactive agent to an active agent.

26-36. -36. (canceled)

66. A method for creating communication between a first blood vessel and a second blood vessel, comprising delivering to a patient a stent graft such that a passageway is created between the first blood vessel and the second blood vessel.

67. The method of claim 66 wherein the first blood vessel is an artery, and the second blood vessel is a vein.

68. The method of claim 66 wherein both the first blood vessel and the second blood vessel are arteries.

69. The method of claim 66 wherein both the first blood vessel and the second blood vessel are veins.

70. The method of claim 66 wherein the stent graft is delivered into a patient in a constrained form and self-expands into place after release of a constraining device.

71. The method of claim 66 wherein the stent graft is delivered to the patient by a balloon catheter.